Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22653460 | 0.81 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL31341190 | 0.80 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL31341297 | 0.80 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL1181029 | 0.80 | NPC1 (0.87) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL6352561 | 0.80 | RAB9A (0.61) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL3358354 | 0.79 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL6352556 | 0.79 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL9214731 | 0.79 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL10583890 | 0.79 | RAB9A (0.59) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL2898452 | 0.78 | NOTUM (0.64) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058447-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | A2A Pharmaceuticals, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| EP-3801529-B1 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | ONCOCUBE THERAPEUTICS LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11622966-B2 | Highly potent TACC3 inhibitor as a novel anticancer drug candidate | A2A PHARMACEUTICALS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230027854-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | COILED THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210220369-A1 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | A2A PHARMACEUTICALS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021097352-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | A2A PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3801529-A2 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | OncoCube Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112469414-A | Highly potent TACC3 inhibitor as novel candidate anticancer drug | 昂科库博疗法有限责任公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| WO-2020018039-A2 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | BANOGLU ERDEN (TR) | 2020-01-23 | — | — | WO | disclosed |
| WO-2012076942-A1 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-06-14 | — | — | WO | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220369-A1 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | TACR3, TAC3, TACR2 | NPC1 288/4885RAB9A 3167/4885SMN1; SMN2 4726/4885 |
| US-11622966-B2 | Highly potent TACC3 inhibitor as a novel anticancer drug candidate | BUB3, TAC3, TACR3 | NPC1 937/4885RAB9A 4138/4885SMN1; SMN2 4346/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | NPC1 1167/4885RAB9A 334/4885SMN1; SMN2 14/4885 |
| US-20230027854-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | PTPRC, NFATC1, PTPRCAP | NPC1 637/4885RAB9A 2191/4885SMN1; SMN2 4119/4885 |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | NPC1 428/4885RAB9A 3098/4885SMN1; SMN2 313/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | NPC1 2053/4885RAB9A 2257/4885SMN1; SMN2 13/4885 |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | NPC1 1464/4885RAB9A 2718/4885SMN1; SMN2 4619/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | NPC1 4147/4885RAB9A 1619/4885SMN1; SMN2 120/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | NPC1 795/4885RAB9A 1496/4885SMN1; SMN2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.